Ascendis Pharma A/S - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
ASND Nasdaq 2836 ascendispharma.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Ascendis Pharma A/S

Ascendis Pharma (ASND):10 Most Profitable Growth Stocks to Buy - Jun 9th, 2026 5:22 pm
Ascendis to Showcase Advances in Treatment of Rare Endocrine Diseases at ENDO 2026 - Jun 8th, 2026 2:59 pm
Assessing Ascendis Pharma (ASND) Valuation After Recent Share Price Weakness - Jun 8th, 2026 10:10 am
European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading; Flat for Week - May 29th, 2026 9:11 am
JPMorgan says large-cap biotech is back as profits and pipelines fuel upside - May 28th, 2026 2:27 pm
European Equities Traded in the US as American Depositary Receipts Track Higher in Tuesday Trading - May 26th, 2026 9:09 am
Spyglass Capital Dumps $26 Million of Global-e Online Amid Stock's 24% Decline - May 20th, 2026 2:41 pm
JPMorgan sees biotech sector at inflection point, resumes coverage on 14 Firms - May 20th, 2026 1:29 pm
StubHub, Jazz Pharmaceuticals upgraded: Wall Street's top analyst calls - May 19th, 2026 7:34 am
European Equities Traded in the US as American Depositary Receipts Open Week Tracking Higher in Monday Trading - May 18th, 2026 9:11 am
Ascendis Pharma (NASDAQ:ASND) Is Posting Healthy Earnings, But It Is Not All Good News - May 15th, 2026 5:26 am
What to Know About This Fund’s $50 Million Exit From Ascendis Pharma - May 14th, 2026 1:05 pm
European Equities Traded in the US as American Depositary Receipts Flat in Wednesday Trading - May 13th, 2026 9:12 am
Energy Fund Yielding 7% and Up 14% in a Year Still Wasn’t Enough to Stop This $3 Million Exit - May 9th, 2026 10:35 am
Ascendis (ASND) Q1 2026 Earnings Call Transcript - May 8th, 2026 9:43 am
European Equities Traded in the US as American Depositary Receipts Heading Lower in Thursday Trading - May 7th, 2026 9:10 am
Ascendis Pharma A/S Q1 Earnings Call Highlights - May 7th, 2026 8:14 am
Ascendis Pharma Reports First Quarter 2026 Financial Results - May 7th, 2026 5:30 am
New 2-Year Data from Pivotal ApproaCH Trial of TransCon® CNP (Navepegritide) Show Pronounced Gains in Growth Outcomes in Children with Achondroplasia Aged ≥5 Years - May 6th, 2026 2:01 pm
Ascendis to Report First Quarter 2026 Financial Results and Provide Business Update on May 7, 2026 - Apr 30th, 2026 2:01 pm